EUVIMEDEUVIMED entdecken
Crossref

Identifying potent inhibitors for Mycobacterium tuberculosis MabA (FabG1)

Debashis Panda iD, Jitendra Maharana iD, Arjun Sharma iD, Sachin B Wadavrao, Abhishek Chowdhury, Monjur Ahmed Laskar, Mahendra K Modi iD, Manabendra D Choudhury iD

Molecular Diversity · 2026

DOI: 10.1007/s11030-025-11205-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Diversity, 2026. Verfasst von Debashis Panda und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Science and Bioinformatics, Assam University, Silchar, Assam, 788011, India. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Enzyme Inhibitors, Antitubercular Agents, Bacterial Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 66 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The surge in drug-resistant Mycobacterium tuberculosis (Mtb) strains poses formidable challenges for tuberculosis treatment, emphasizing the pressing need to explore novel therapeutic agents. Mycolic acids, essential for bacterial cell wall formation, are synthesized by two fatty acid synthase (FAS) systems: FAS-I and FAS-II. MabA, an enzyme in the FAS-II system, is vital in the second step of fatty acid biosynthesis and is responsible for the elongation of mycolic acids. In this study, we screened 1,792,771 compounds from seven different databases to screen prospective inhibitors of MabA, an emerging therapeutic target for Mtb. Using a combination of molecular docking, all-atom molecular dynamics simulations, and binding free energy calculations, we identified 48 novel lead compounds from five distinct classes that exhibit significant binding activity against MabA. Of these, 47 compounds demonstrated significantly higher MM/PBSA binding free energy than the only reported MabA inhibitor, compound 29. Altogether, our findings mark a significant advancement towards the rational design of novel therapeutics aimed at combating mycobacterial infections and overcoming drug resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisEnzyme InhibitorsAntitubercular AgentsBacterial ProteinsMolecular Docking SimulationMolecular Dynamics SimulationProtein BindingDrug Discovery

Stichwörter der Autor:innen

Mycobacterium tuberculosisFAS–II systemMD simulationMabAVirtual screening

Substanzen

Enzyme InhibitorsAntitubercular AgentsBacterial Proteins

Autor:innen und Institutionen

  • Department of Life Science and Bioinformatics, Assam University, Silchar, Assam, 788011, India.
  • DBT-APSCS&T Centre of Excellence for Bioresources and Sustainable Development, Kimin, Arunachal Pradesh, 791121, India.
  • Department of Agricultural Biotechnology, Assam Agricultural University, Jorhat, Assam, 785013, India.
  • Institute of Biological Chemistry, Academia Sinica, Taipei, 11529, Taiwan.
  • Department of Chemistry and Biochemistry, Purdue University Fort Wayne, Fort Wayne, IN, 46805, USA.
  • OBC Division, CSIR-Indian Institute of Chemical Technology, Tarnaka, Hyderabad, Telangana, 500007, India.

ORCID-Profile: Debashis Panda, Jitendra Maharana, Arjun Sharma, Mahendra K Modi, Manabendra D Choudhury

Zitieren

APA

Panda, D., Maharana, J., Sharma, A., Wadavrao, S. B., Chowdhury, A., Laskar, M. A., Modi, M. K., & Choudhury, M. D. (2026). Identifying potent inhibitors for Mycobacterium tuberculosis MabA (FabG1). Molecular Diversity. https://doi.org/10.1007/s11030-025-11205-7

Vancouver

Panda D, Maharana J, Sharma A, Wadavrao SB, Chowdhury A, Laskar MA, et al. Identifying potent inhibitors for Mycobacterium tuberculosis MabA (FabG1). Molecular Diversity. 2026. doi:10.1007/s11030-025-11205-7

BibTeX
@article{Panda2026,
  author = {Panda, Debashis and Maharana, Jitendra and Sharma, Arjun and Wadavrao, Sachin B and Chowdhury, Abhishek and Laskar, Monjur Ahmed and Modi, Mahendra K and Choudhury, Manabendra D},
  title = {Identifying potent inhibitors for Mycobacterium tuberculosis MabA (FabG1)},
  journal = {Molecular Diversity},
  year = {2026},
  doi = {10.1007/s11030-025-11205-7}
}
Kostenlos starten →